TAKEDA-SPONSORED
Fall Clinical Dermatology Poster Details
Available for Review at the 2026 Fall Clinical Dermatology Conference
All posters are available for in person viewing in Cristal 1, 3, 5, 7. Oct. 9-11 during poster hall hours.
Moderate to Severe Plaque Psoriasis
Poster
Depth of Psoriasis Area and Severity Index (PASI) response with zasocitinib, a once-daily oral TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis: a post hoc analysis of two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002)
Mark Lebwohl, Kenneth B Gordon, Peter Foley, Laura Ferris, Anna López Ferrer, Leandro L Leite, Hsien-Yi Chiu, Masatoshi Abe, Nada Elbuluk, Edith Angellotti, Wenwen Zhang, Jean-Phillip Okhovat, Richard B Warren [Original]
Poster
Onset, resolution and management of acne in phase 3 trials of zasocitinib in adults with moderate-to-severe plaque psoriasis (LATITUDE-PsO-3001 and 3002)
Linda Stein Gold, Paula C Luna, Melinda J Gooderham, Alice B Gottlieb, Darryl Toth, Angela Y Moore, Nina Magnolo, Shinichi Imafuku, Nan Yu, Helen Sile,
Michael Fogel, Jason Tackett, Yuan Zhao, Jean-Phillip Okhovat, Leon Kircik [Original]
Poster
Patients who achieved rapid itch reduction with zasocitinib, a once-daily oral TYK2 inhibitor, showed sustained skin clearance through 52 weeks: a post hoc analysis of two randomized phase 3 trials in adults with moderate-to-severe plaque psoriasis (LATITUDE-PsO-3001 and 3002)
Lawrence Green, Edward Lain, Vivian Laquer, Adelaide Hebert, Jamie Weisman, Marni C Wiseman, Joanna Narbutt, Athanasios Tsianakas, Chul Jong Park,
Michael Fogel, Jason Tackett, Junyao Wang, Jean-Phillip Okhovat, Robert Bissonnette [Original]
Poster
Dynamic interplay between scratching and sleep in psoriasis and atopic dermatitis.
Pietro Artoni, Ronaldo Fujii, Marta Karas, Brian Tracey, Tarik Yardibi, Xuefang Wu, Richard Hausman, Colleen Fetherston, Nina Shaafi Kabiri, Kevin Thomas, Warren Winkelman, Dmitri Volfson, Tina Bhutani, Francesco Onorati [Original]
Poster
Understanding plaque psoriasis from the US patient perspective to inform a patient-centric value framework: a survey on signs and symptoms, impacts on daily life, and treatment priorities.
April W Armstrong, Jason Hyman, Adrian Jewett, Brandon Foster, Sara Loniewski, Adriana Voci, Christopher Evans, Stephen Lee, John Caloyeras [Original]
Poster
Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates durable efficacy for up to 60 weeks in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002) [Encore]
April W Armstrong, Linda Stein Gold, Christopher G Bunick, Paula C Luna, Antonio Costanzo, Nina Magnolo, Peter Foley, Francesca Prignano, Jianzhong Zhang, Michael Fogel, Jason Tackett, Yang Chen, Warren Winkelman, Melinda Gooderham [Original presentation: EADV 2026]
date-card-poster
Poster
Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates superior skin clearance (PASI 100) versus an approved oral TYK2 inhibitor, deucravacitinib, and a consistent safety profile in moderate-to-severe plaque psoriasis: a randomized phase 3 intraclass head-to-head trial [Encore]
Linda Stein Gold, Adam Reich, Darryl Toth, James Q Del Rosso, Laura K Ferris, Mireille Ruer-Mulard, Shinichi Imafuku, Edith Angellotti, Sean Liu, Wenwen Zhang, Michael Chen, Warren Winkelman, Melinda Gooderham [Original presentation: EADV 2026]